[go: up one dir, main page]

UY37700A - Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf - Google Patents

Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf

Info

Publication number
UY37700A
UY37700A UY0001037700A UY37700A UY37700A UY 37700 A UY37700 A UY 37700A UY 0001037700 A UY0001037700 A UY 0001037700A UY 37700 A UY37700 A UY 37700A UY 37700 A UY37700 A UY 37700A
Authority
UY
Uruguay
Prior art keywords
disorders
modulators
imidazol
tnf activity
derivatives fused
Prior art date
Application number
UY0001037700A
Other languages
English (en)
Inventor
Yann Foricher
De Haro Garcia Teresa
Mengyang Xuan
Zhaoning Zhu
Christopher Brookings Daniel
Andrew Johnson James
Tracey Horsley Helen
Clive Hutchings Martin
Malcolm Maccoss
Original Assignee
Sanofi Sa
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58632834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY37700(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa, Ucb Biopharma Sprl filed Critical Sanofi Sa
Publication of UY37700A publication Critical patent/UY37700A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de fórmula (I) como se define en la memoria descriptiva, o una sal farmacéuticamente aceptable del mismo, como moduladores potentes de la actividad de TNFa humano, los cuales por consiguiente son beneficiosos para el tratamiento y/o la prevención de diversas enfermedades humanas, incluyendo trastornos autoinmunológicos e inflamatorios; trastornos neurológicos y neurodegenerativos; dolor y trastornos nociceptivos; trastornos cardiovasculares; trastornos metabólicos; trastornos oculares; y trastornos oncológicos.
UY0001037700A 2017-04-25 2018-04-25 Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf UY37700A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17168027 2017-04-25

Publications (1)

Publication Number Publication Date
UY37700A true UY37700A (es) 2018-11-30

Family

ID=58632834

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037700A UY37700A (es) 2017-04-25 2018-04-25 Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf

Country Status (32)

Country Link
US (4) US10980814B2 (es)
EP (2) EP3939980B1 (es)
JP (2) JP7083358B2 (es)
KR (1) KR102565132B1 (es)
CN (1) CN110582495B (es)
AR (1) AR111426A1 (es)
AU (1) AU2018259040B2 (es)
CA (1) CA3058980A1 (es)
CL (1) CL2019002875A1 (es)
CO (1) CO2019012856A2 (es)
CR (1) CR20190526A (es)
DK (1) DK3615534T3 (es)
EA (1) EA039049B1 (es)
ES (2) ES2956555T3 (es)
HR (1) HRP20211927T1 (es)
HU (1) HUE056593T2 (es)
IL (1) IL269890B (es)
LT (1) LT3615534T (es)
MA (2) MA49055B1 (es)
MX (1) MX2019012443A (es)
MY (1) MY197212A (es)
PE (1) PE20200662A1 (es)
PH (1) PH12019502182B1 (es)
PL (2) PL3939980T3 (es)
PT (2) PT3615534T (es)
RS (1) RS62596B1 (es)
SG (1) SG11201908871SA (es)
SI (1) SI3615534T1 (es)
TW (1) TWI801378B (es)
UY (1) UY37700A (es)
WO (1) WO2018197503A1 (es)
ZA (1) ZA201906255B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017167995A1 (en) * 2016-04-01 2017-10-05 Ucb Biopharma Sprl Fused hexacyclic imidazole derivatives as modulators of tnf activity
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
JP7429694B2 (ja) * 2018-10-24 2024-02-08 ユーシービー バイオファルマ エスアールエル Ｔｎｆ活性のモジュレータとしての縮合五環式イミダゾール誘導体
EP4622981A1 (en) 2022-11-23 2025-10-01 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
CN121038791A (zh) 2023-04-26 2025-11-28 赛诺菲 使用肿瘤坏死因子α的小分子抑制剂治疗银屑病
TW202513567A (zh) * 2023-06-09 2025-04-01 大陸商上海翰森生物醫藥科技有限公司 五環類衍生物抑制劑、其製備方法與應用
WO2025008402A1 (en) 2023-07-04 2025-01-09 Sanofi Crystalline form
CN119630670A (zh) 2023-08-16 2025-03-14 瑞雷拉公司 TNFα活性调节剂及其用途
TW202527952A (zh) 2023-09-29 2025-07-16 法商賽諾菲公司 合成方法
WO2025201449A1 (zh) * 2024-03-27 2025-10-02 海思科医药集团股份有限公司 一种杂环衍生物及其在医药上的应用
WO2025218735A1 (zh) * 2024-04-17 2025-10-23 上海翰森生物医药科技有限公司 五环类衍生物抑制剂、其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104428293B (zh) * 2012-06-11 2018-06-08 Ucb生物制药私人有限公司 调节TNFα的苯并咪唑类
BR112015000675B1 (pt) * 2012-07-13 2022-07-12 UCB Biopharma SRL Derivados de imidazopiridina como moduladores da atividade de tnf
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
PE20170693A1 (es) * 2014-10-03 2017-06-13 Ucb Biopharma Sprl Derivados de imidazol pentaciclicos fusionados
AR104291A1 (es) * 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf

Also Published As

Publication number Publication date
CO2019012856A2 (es) 2020-01-17
PE20200662A1 (es) 2020-06-11
CN110582495A (zh) 2019-12-17
AU2018259040A1 (en) 2019-10-31
KR102565132B1 (ko) 2023-08-08
PL3615534T3 (pl) 2022-01-31
US20230250105A1 (en) 2023-08-10
CN110582495B (zh) 2022-04-01
MX2019012443A (es) 2020-01-13
KR20190141200A (ko) 2019-12-23
JP2022116233A (ja) 2022-08-09
EA039049B1 (ru) 2021-11-26
TWI801378B (zh) 2023-05-11
NZ758198A (en) 2024-01-26
EP3615534A1 (en) 2020-03-04
JP7299382B2 (ja) 2023-06-27
MY197212A (en) 2023-06-01
HRP20211927T1 (hr) 2022-03-18
US20210252012A1 (en) 2021-08-19
EP3939980A1 (en) 2022-01-19
BR112019020314A2 (pt) 2020-04-28
AU2018259040B2 (en) 2022-04-28
SG11201908871SA (en) 2019-10-30
ES2956555T3 (es) 2023-12-22
JP7083358B2 (ja) 2022-06-10
EP3939980B1 (en) 2023-07-26
TW201841918A (zh) 2018-12-01
MA49055A (fr) 2021-05-05
WO2018197503A1 (en) 2018-11-01
US10980814B2 (en) 2021-04-20
IL269890B (en) 2022-03-01
MA49055B1 (fr) 2021-12-31
LT3615534T (lt) 2021-11-25
JP2020517637A (ja) 2020-06-18
PH12019502182A1 (en) 2020-06-08
ZA201906255B (en) 2021-01-27
EP3615534B1 (en) 2021-09-15
CL2019002875A1 (es) 2020-03-06
US20200046723A1 (en) 2020-02-13
AR111426A1 (es) 2019-07-10
SI3615534T1 (sl) 2022-01-31
PT3939980T (pt) 2023-08-07
PL3939980T3 (pl) 2024-02-05
US20250127795A1 (en) 2025-04-24
DK3615534T3 (da) 2021-10-18
CR20190526A (es) 2020-01-07
MA57699B1 (fr) 2023-11-30
CA3058980A1 (en) 2018-11-01
PH12019502182B1 (en) 2024-01-31
EA201992407A1 (ru) 2020-04-06
PT3615534T (pt) 2021-10-21
HUE056593T2 (hu) 2022-02-28
RS62596B1 (sr) 2021-12-31
ES2893807T3 (es) 2022-02-10

Similar Documents

Publication Publication Date Title
UY37700A (es) Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf
ECSP17027306A (es) Derivados de imidazol pentacíclicos fusionados
CA2931589C (en) Fused bicyclic heteroaromatic derivatives as modulators of tnf activity
MX2016011038A (es) Compuestos para el tratamiento de trastornos mediados por complemento.
BR112018069936A2 (pt) derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf
BR112016012997A2 (pt) Derivados de benzimidazóis tricíclicos fundidos como moduladores de atividade de tnf
BR112016012990A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
MX2017015521A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
MX386752B (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX381313B (es) Derivados de benzimidazol como moduladores de ror-gamma
BR112016012258A2 (pt) Derivados de tetra-hidrobenzimidazol como moduladores de atividade de tnf
BR112018069937A2 (pt) derivados de imidazol hexacíclicos fundidos como moduladores de atividade do tnf
BR112016012261A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
BR112018069941A2 (pt) derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf
TR201907702T4 (tr) Tnf aktivitesinin modülatörleri olarak triazolopiridin türevleri.
EA201792686A1 (ru) Производные индазола в качестве модуляторов активности tnf
BR112016012254A2 (pt) Derivados de triazolpiridazina como moduladores de atividade de tnf
BR112016011527A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
TR201910983T4 (tr) Tnf aktivitesinin modülatörleri olarak imidazotiazol türevleri.
EA201892149A1 (ru) Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf
CO2017011020A2 (es) Derivados de 6-morfolinil-2-pirazolil-9h-purina y su uso como inhibidores de fosfoinositol-3-cinasa (pi3k)
MX2019006033A (es) Derivado de benzimidazol sustituido como modulador de la actividad del factor de necrosis tumoral.
EP3445334A4 (en) NANOLIPOSOMES FOR THE DELAYED RELEASE OF TACROLIMUS FOR THE TREATMENT OF EYE DISEASES OF THE ANTERIOR SEGMENT
HK1240916A1 (en) Fused pentacyclic imidazole derivatives
NZ758198B2 (en) Fused pentacyclic imidazole derivatives as modulators of tnf activity

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231103